AUTL - Autolus Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
31.03
-0.37 (-1.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close31.40
Open31.71
Bid26.50 x 900
Ask50.00 x 800
Day's Range30.87 - 31.88
52 Week Range19.17 - 53.24
Volume158,661
Avg. Volume84,122
Market Cap1.246B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.00
Trade prices are not sourced from all markets
  • Alexandria Fully Leases New Built-to-Suit Facility to Autolus
    Zacks4 days ago

    Alexandria Fully Leases New Built-to-Suit Facility to Autolus

    Alexandria Real Estate Equities' (ARE) new build-to-suit project in Rockville will serve as the U.S. headquarters and a commercial scale manufacturing site for Autolus.

  • Biotech to create 170 jobs, invest $28M in new Rockville HQ
    American City Business Journals6 days ago

    Biotech to create 170 jobs, invest $28M in new Rockville HQ

    London-based Autolus Therapeutics said Monday it plans to create up to 170 jobs at its new U.S. headquarters and manufacturing facility in Rockville over the next three years and invest about $28 million in the 85,000-square-foot project planned for the Shady Grove Life Sciences Center. The project will get a boost from a $200,000 Economic Development Fund conditional grant from the county, while the state of Maryland is providing a $525,000 Advantage Maryland conditional loan. Autolus' new Montgomery County facility is part of a plan by the company to roughly double its work force from 200 employees today to nearly 400 in the next 12 to 18 months, said Matthias Alder, senior vice president and chief business officer of Autolus, who is leading efforts to establish the new headquarters.

  • PR Newswire6 days ago

    Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

    LONDON, Jan. 14, 2019 /PRNewswire/ -- Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus' U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually.

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journals11 days ago

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • London biotech firm planning new U.S. HQ, research facility in Rockville
    American City Business Journals11 days ago

    London biotech firm planning new U.S. HQ, research facility in Rockville

    After selecting Maryland last year for its U.S. headquarters, London-based biopharmaceutical firm Autolus Therapeutics PLC is working to open the new office at an 85,000-square-foot research and development building in Rockville. The Montgomery County Planning Board will vote Thursday the site plan. If approved, the company's new headquarters would go up on an 8-acre parcel at 9950 Medical Center Drive, which is owned by landlord Alexandria Real Estate Equities Inc. (NYSE: ARE), a California-based real estate investment trust with a focus on life sciences and tech campuses.

  • PR Newswirelast month

    Autolus Therapeutics to Join NASDAQ Biotechnology Index

    LONDON, Dec. 20, 2018 /PRNewswire/ -- Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI) as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018. "We believe that Autolus' inclusion in the NASDAQ Biotechnology Index reflects growing awareness among the investment community of our proprietary T cell programming technology and our robust pipeline of therapeutic candidates under development for the treatment of cancer," said Dr. Christian Itin, chairman and chief executive officer of Autolus. The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB), and which also meet other eligibility criteria.

  • PR Newswire2 months ago

    Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes

    LONDON , December 3, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus ...

  • PR Newswire2 months ago

    Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH

    LONDON , December 3, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its portfolio company, ...

  • PR Newswire2 months ago

    Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting

    - Initial results were presented from ongoing Phase 1/2 trials in pediatric acute lymphoblastic leukemia (AMELIA trial) and diffuse B cell lymphoma (ALEXANDER trial) - LONDON , Dec. 2, 2018 /PRNewswire/ ...

  • PR Newswire2 months ago

    Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

    -First patient dosed in Phase 1/2 trial of AUTO4 in TRBC1-positive peripheral T cell lymphoma- -Preclinical data for AUTO5 targeting TRBC2-positive peripheral T cell lymphoma presented at the 60th Annual ...

  • PR Newswire2 months ago

    Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

    LONDON , Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it ...

  • PR Newswire3 months ago

    Autolus Therapeutics to Present New Data at the ASH Annual Meeting

    LONDON , November 2, 2018 /PRNewswire/ -- Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes one of its Group Businesses, ...

  • PR Newswire3 months ago

    Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting

    - Company to Present One Oral Presentation and Two Posters - LONDON , Nov. 1, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation ...

  • PR Newswire3 months ago

    Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference

    LONDON , Oct. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. ...

  • PR Newswire3 months ago

    Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality

    Company Further Strengthens Executive Team to Support Promising Clinical Pipeline LONDON , Oct. 17, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company ...

  • Reuters4 months ago

    UK biotech raises bumper $2 billion, despite Brexit blues

    LONDON (Reuters) - Britain's biotechnology industry has raised a bumper 1.56 billion pounds in the first eight months of this year, surpassing the 1.2 billion reached in the whole of 2017, despite anxiety ...

  • T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics
    Market Realist4 months ago

    T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics

    Headquartered in London, Autolus Therapeutics (AUTL) is focused on developing next-generation T-cell therapies targeting multiple solid tumor and hematological indications. According to Autolus Therapeutics’ September investor presentation, the company expects to report proof-of-concept data from five programs in 2019.

  • PR Newswire5 months ago

    Autolus to Present at Upcoming Investor Conferences

    LONDON , Aug. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management ...

  • Benzinga7 months ago

    The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Eidos Therapeutics, Inc. (NASDAQ: EIDX ) will issue 6.25 million shares between $15 and $17 Wednesday on the Nasdaq. The ...